Expression of 11β-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: Potential role in pathogenesis and as targets for treatments

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages 589-598

  Patel, Pushpa ^a   Hardy, Rowan ^a   Sumathi, Vaiyapuri ^b   Bartle, Gillian ^b   Kindblom, Lars Gunnar ^b   Grimer, Robert ^c   Bujalska, Iwona ^a   Stewart, Paul M ^a   Rabbitt, Elizabeth ^a   Gittoes, Neil J L ^a   Cooper, Mark S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; CISPLATIN; DEHYDRODEXAMETHASONE; DEXAMETHASONE; DEXAMETHASONE DERIVATIVE; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; IFOSFAMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BONE BIOPSY; BONE RESECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; DRUG DISCOVERY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; YOUNG ADULT;

EID: 84864413893     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0079     Document Type: Article

References (23)

1. Best R, Nelson SM & Walker BR 1997 Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11β-hydroxysteroid dehydrogenase in vitro and in vivo. Journal of Endocrinology 153 41-48. (doi:10.1677/joe.0.1530041)
2. Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, Stewart PM & Hewison M 1999 Characterization of 11β-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. Journal of Endocrinology 161 455-464. (doi:10.1677/joe.0.1610455)
3. Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP & Grimer RJ 2005 Pre- and postchemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. European Journal of Cancer 41 2846-2852. (doi:10.1016/j.ejca.2005.07.024)
4. Bui T & Thompson CB 2006 Cancer's sweet tooth. Cancer Cell 9 419-420. (doi:10.1016/j.ccr.2006.05.012)
5. Cooper MS 2004 Sensitivity of bone to glucocorticoids. Clinical Science 107 111-123. (doi:10.1042/CS20040070)
6. Cooper M & Stewart PM 1998 The syndrome of apparent mineralocorticoid excess. Quarterly Journal of Medicine 91 453-455. (doi:10.1093/qjmed/91.7.453)
7. Cooper MS & Stewart PM 2009 11β-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. Journal of Clinical Endocrinology and Metabolism 94 4645-4654. (doi:10.1210/jc.2009-1412)
8. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M & Stewart PM 2000 Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 27 375-381. (doi:10.1016/S8756-3282(00)00344-6)
9. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M & Stewart PM 2001 Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Journal of Bone and Mineral Research 16 1037-1044. (doi:10.1359/jbmr.2001.16.6.1037)
10. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M & Stewart PM 2002 Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. Journal of Bone and Mineral Research 17 979-986. (doi:10.1359/jbmr.2002.17.6.979)
11. Coulter CL, Smith RE, Stowasser M, Sasano H, Krozowski ZS & Gordon RD 1998 Expression of 11βHSD-2 in human adrenal cortical carcinoma and adenoma. Endocrine Research 24 875-876. (doi:10.3109/07435809809032701)
12. Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W & Bahr V 2002 11β- Hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mine. Journal of Clinical Endocrinology and Metabolism 87 5695-5701. (doi:10.1210/jc.2002-020970)
13. Eyre LJ, Rabbitt EH, Bland R, Hughes SV, Cooper MS, Sheppard MC, Stewart PM & Hewison M 2001 Expression of 11β-hydroxysteroid dehydrogenase in rat osteoblastic cells: pre-receptor regulation of glucocorticoid responses in bone. Journal of Cellular Biochemistry 81 453-462. (doi:10.1002/1097- 4644(20010601)81:3〈453::AID-JCB1059〉3.0.CO;2-Z)
14. Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, Gittoes NJ, Buckley CD, Raza K & Cooper MS 2008 Local and systemic glucocorticoid metabolism in inflammatory arthritis. Annals of the Rheumatic Diseases 67 1204-1210. (doi:10.1136/ard.2008.090662)
15. Kudawara I, Ueda T, Yoshikawa H, Miyama T, Yamamoto T & Nishizawa Y 2001 In vivo inhibition of tumour growth by dexamethasone in murine osteosarcomas. European Journal of Cancer 37 1703-1708. (doi:10.1016/S0959- 8049(01)00185-X)
16. Marina N, Gebhardt M, Teot L & Gorlick R 2004 Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9 422-441. (doi:10.1634/ theoncologist.9-4-422)
17. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC & Weinstein RS 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145 1835-1841. (doi:10.1210/en.2003-0990)
18. Rabbitt E, Lavery GG, Walker EA, Cooper MS, Stewart PM & Hewison M 2002 Pre-receptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB Journal 16 36-44. (doi:10.1096/fj.01-0582com)
19. Rabbitt EH, Ayuk J, Boelaert K, Sheppard MC, Hewison M, Stewart PM & Gittoes NJ 2003 Abnormal expression of 11β-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene 22 1663-1667. (doi:10.1038/sj.onc.1206293)
20. Raymond AK, Ayala AG & Knuutila S 2002 Conventional osteosarcoma. In WHO Classification of Tumours. Tumours of Soft Tissue and Bone, pp 264-270. Eds, P Kleihues, L Sobin, C Fletcher et al. Lyon, France: IARC Press.
21. Sai S, Nakagawa Y, Yamaguchi R, Suzuki M, Sakaguchi K, Okada S, Seckl JR, Ohzeki T & Chapman KE 2011 Expression of 11β-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells. Leukemia Research 35 1644-1648. (doi:10.1016/j.leukres.2011.07. 002)
22. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M & Stewart PM 2004 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews 25 831-866. (doi:10.1210/er.2003-0031)
23. Wafa H & Grimer RJ 2006 Surgical options and outcomes in bone sarcoma. Expert Review of Anticancer Therapy 6 239-248. (doi:10.1586/14737140.6. 2.239)